Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

9 terminated/withdrawn out of 18 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

22%

4 trials in Phase 3/4

Results Transparency

0 of 9 completed trials have results

Key Signals

7 terminated

Enrollment Performance

Analytics

Phase 1

6(37.5%)

Phase 2

6(37.5%)

Phase 3

3(18.8%)

Phase 4

1(6.3%)

16Total

Phase 1(6)

Phase 2(6)

Phase 3(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials

NCT01908933Phase 3Withdrawn

Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema

Role: lead

NCT01320566Phase 2Terminated

A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema

Role: lead

NCT01520740Phase 4Terminated

Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema

Role: lead

NCT01449175Terminated

A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema

Role: lead

NCT01449292Phase 3Terminated

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Role: lead

NCT01520064Terminated

Post Market Registry Study of the AeriSeal System

Role: lead

NCT01051258Phase 1Completed

AeriSeal System for Lung Volume Reduction

Role: lead

NCT00630227Phase 2Completed

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

Role: lead

NCT00435253Phase 2Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Role: lead

NCT00515164Phase 2Completed

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Role: lead

NCT01181466Phase 2Completed

AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema

Role: lead

NCT00884962Phase 1Completed

A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema

Role: lead

NCT00716053Phase 3Withdrawn

Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema

Role: lead

NCT00517998Phase 1Completed

Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Role: lead

NCT00205920Phase 2Terminated

Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Role: lead

NCT00085852Phase 1Completed

US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation

Role: lead

NCT00205907Phase 1Terminated

Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Role: lead

NCT00347659Phase 1Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Role: lead

All 18 trials loaded